# Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA

> **NCT05461664** · — · RECRUITING · sponsor: **Xinhua Zhang, MD** · enrollment: 74 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumors
- Unresectable Solid Tumor
- Recurrent Metastatic Malignant Neoplasm

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05461664
- **Lead sponsor:** Xinhua Zhang, MD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-10
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2025-02-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05461664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05461664, "Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05461664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*